Alluvi, previously BI 4744, represents a significant breakthrough in weight control therapy. This dual activator targeting both GLP-1 and GIP targets demonstrates remarkable results in clinical trials, possibly https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/